The plaintiff, John Doe, alleges that not having access to a community pharmacist will limit his ability to gain counseling on potential drug interactions. United Healthcare settled a similar action earlier in 2014. Consumer groups have also alleged discrimination against HIV patients by insurers over drug access in Florida.
For the second time in 2014, a national insurer has been sued by a California consumer group for requiring persons with HIV/AIDS to purchase prescriptions through its mail-order specialty pharmacy.
Aetna Inc. was sued December 19, 2014, about a month after sending notices to its California enrollees informing them of the policy change that will take effect January 1, 2015.
The unnamed plaintiff, John Doe, says in the suit filed in federal court that the change is discriminatory, because it will deprive HIV-positive patients of “essential counseling from an expert pharmacist at a community pharmacy who knows their medical history and who, working directly with patients in face-to-face interactions, is best positioned to detect potentially life-threatening adverse drug interactions and dangerous side effects.”
Persons with HIV/AIDS could elect to obtain their prescriptions from a community pharmacy. However, under the policy change, Aetna would consider that purchase out-of-network, which the suit alleges would cost patients “thousands of dollars more” each month. Prior to the policy change, co-payments were fixed at $20 to $70 per prescription.
The new program charges a 20% coinsurance, up to a maximum of $150 per prescription, which the suit alleges is discriminatory in itself.
Aetna official Cynthia Michener defended the program and the proposed changes in a statement. “As part of our ongoing strategy to do all we can to keep our health plans affordable and help with medication adherence, Aetna moved HIV medications to our specialty drug list. This list includes a number of high-cost medications that treat complex conditions that require close patient monitoring,” Michener said.
Earlier in 2014, United Healthcare faced a similar action and settled, agreeing to let HIV/AIDS patients who did not want to participate in a mail order program opt out through a simple procedure. United Healthcare and its specialty pharmacy also agreed to set up a designated toll-free customer service line to handle calls about the exemption process.
Consumer watchdog lawsuits have also occurred in Florida, where advocates had accused national insurers of overcharging HIV/AIDS patients for prescriptions or limiting their ability to obtain them under the Affordable Care Act (ACA), which gave some HIV-positive persons access to health insurance for the first time in their lives.
The ACA ban against barring persons with pre-existing conditions from obtaining coverage has been a game-changer for persons who have outlived the frightening early days of the disease, when diagnosis was the equivalent of a death sentence. Today, the CDC officially considers HIV a chronic condition, albeit one that requires a lifetime regimen of expensive medications.
In September, The American Journal of Managed Care published a well-read editorial by Gerry Oster, PhD, and co-editor-in-chief A. Mark Fendrick, MD, about an emerging pattern in which health plans have created higher-priced non-preferred tiers not only for drugs still on patent, but also for generic drugs. In some cases, non-preferred drugs included those for which there was no lower-cost alternative. HIV drugs were among those found to be priced in the non-preferred generic category in a survey by the authors.
The practice has caught the attention of Congress, which has noticed a sudden escalation in generic drug prices, with no obvious explanation.
Around the Web
Aetna Faces Class Action Over Changes to HIV/AIDS Program
United Healthcare Agrees to Settle HIV/AIDS Discrimination Lawsuit
Is All “Skin in the Game” Fair Game? The Problem With Non-Preferred Generics
Second Florida Insurer Strikes Deal with State Over HIV Drugs
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More